Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts…
Community, Culture, Applications & Research
Explore the main themes, entities and connections around Crizotinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
kinase alk lymphoma lung cell treatment non-small anaplastic cancer malignant patients gene number tumors fusion nsclc growth also refractory factor
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Crizotinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Crizotinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Crizotinib | ATC code | L01ED01 (WHO) | 1.00 | infobox |
| Crizotinib | Bioavailability | 43% | 1.00 | infobox |
| Crizotinib | CAS Number | 877399-52-5 N | 1.00 | infobox |
| Crizotinib | ChEBI | CHEBI:64310 N | 1.00 | infobox |
| Crizotinib | ChEMBL | ChEMBL601719 Y | 1.00 | infobox |
| Crizotinib | ChemSpider | 9801307 Y | 1.00 | infobox |
| Crizotinib | CompTox Dashboard (EPA) | DTXSID701009329 | 1.00 | infobox |
| Crizotinib | DrugBank | DB08700 Y | 1.00 | infobox |
| Crizotinib | ECHA InfoCard | 100.166.440 | 1.00 | infobox |
| Crizotinib | Elimination half-life | 42 hours | 1.00 | infobox |
| Crizotinib | Excretion | Faeces (63%), urine (22%) | 1.00 | infobox |
| Crizotinib | Formula | C21H22Cl2FN5O | 1.00 | infobox |
| Crizotinib | IUPHAR/BPS | 4903 | 1.00 | infobox |
| Crizotinib | KEGG | D09731 N | 1.00 | infobox |
| Crizotinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Crizotinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Crizotinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Crizotinib | Legal status | US: ℞-only | 1.00 | infobox |
| Crizotinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Crizotinib | License data | US DailyMed: Crizotinib | 1.00 | infobox |
| Crizotinib | MedlinePlus | a612018 | 1.00 | infobox |
| Crizotinib | Metabolism | Liver (CYP3A4/CYP3A5-mediated) | 1.00 | infobox |
| Crizotinib | Molar mass | 450.34 g·mol−1 | 1.00 | infobox |
| Crizotinib | Other names | PF-02341066 1066 | 1.00 | infobox |
| Crizotinib | PDB ligand | VGH (PDBe, RCSB PDB) | 1.00 | infobox |
| Crizotinib | Pregnancy category | AU: D | 1.00 | infobox |
| Crizotinib | Protein binding | 91% | 1.00 | infobox |
| Crizotinib | PubChem CID | 11626560 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.